RENOVORX
RenovoRx is a developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. RenovoRx received FDA clearance for the RenovoCath™ RC120 and is currently introducing this innovative technology to the clinical market. RenovoRx has a motivated Management Team with broad experience and an exciting vision for the future of targeted delivery. The company also has a broad Advisory Board of intervention... al radiologists, surgical oncologists and gastroenterologists that guide the company's clinical development strategies. RenovoRx is backed by a strong Board of Directors committed to long-term, continuous support of the company, whose members provide critical expertise in the medical and biotechnology industry and the visionary thinking to succeed.
RENOVORX
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2009-01-01
Address:
Los Altos, California, United States
Country:
United States
Website Url:
http://www.renovorx.com
Total Employee:
1+
Status:
Active
Contact:
650-284-4433
Total Funding:
10.12 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Advisors List
Advisor
Advisor
Board_member
Advisor
Advisor
Advisor
Board_member
Advisor
Current Employees Featured
James M. Ahlers Chief Financial Officer @ RenovoRx
Chief Financial Officer
2022-07-15
Ramtin Agah Chief Medical Officer @ RenovoRx
Chief Medical Officer
Shaun Bagai CEO @ RenovoRx
CEO
2014-06-01
Founder
Stock Details
Investors List
Boston Scientific
Boston Scientific investment in Series D - RenovoRx
Astia Angels
Astia Angels investment in Series D - RenovoRx
btov Partners
btov Partners investment in Series D - RenovoRx
Golden Seeds
Golden Seeds investment in Series D - RenovoRx
Portfolia
Portfolia investment in Series A - RenovoRx
Barbara Clarke
Barbara Clarke investment in Series A - RenovoRx
Plug and Play
Plug and Play investment in Series C - RenovoRx
Next Wave/Portfolia Angel Fund
Next Wave/Portfolia Angel Fund investment in Series C - RenovoRx
Golden Seeds
Golden Seeds investment in Series C - RenovoRx
Astia Angels
Astia Angels investment in Series C - RenovoRx
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-19 | RenovoRx Appoints James Ahlers as Chief Financial Officer |
Official Site Inspections
http://www.renovorx.com Semrush global rank: 4.7 M Semrush visits lastest month: 2.05 K
- Host name: 151.101.130.159
- IP address: 151.101.130.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "RenovoRx"
RenovoRx - Crunchbase Company Profile & Funding
RenovoRx is a developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. RenovoRx …See details»
About Us - RenovoRx
RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate is a novel oncology …See details»
Leadership Team - RenovoRx
Shaun R. Bagai Chief Executive Officer. Mr. Bagai has served as our Chief Executive Officer and director since June 2014. Prior to joining us, Mr. Bagai led Global Market Development for …See details»
Company Information :: RenovoRX, Inc. (RNXT)
RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. The company’s mission is to lead a revolution in oncology …See details»
RenovoRX, Inc. (RNXT)
Feb 26, 2025 RenovoRX, Inc. 2570 W. El Camino Real Suite 320 Mountain View, CA 94040 info@renovorx.com. Investor Relations. KCSA Strategic Communications Valter Pinto or Jack …See details»
RenovoRx (Nasdaq: RNXT) - LinkedIn
RenovoRx (Nasdaq: RNXT) is a life sciences company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to improve ...See details»
RenovoRx, Inc. - AnnualReports.com
RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical needs. The Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to …See details»
RenovoRx - Funding, Financials, Valuation & Investors - Crunchbase
RenovoRx is registered under the ticker NASDAQ:RNXT . Their stock opened with $9.00 in its Aug 25, 2021 IPO. RenovoRx is funded by 11 investors. Boston Scientific and Astia Angels …See details»
RenovoRx - Overview, News & Similar companies | ZoomInfo.com
May 30, 2024 RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024 LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. …See details»
RenovoRx Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors. It offers a therapy platform, RenovoRx Trans …See details»
Presentations :: RenovoRX, Inc. (RNXT)
2570 W. El Camino Real, Suite 320 Mountain View, CA 94040. (650) 284-4433. (650) 397-4433See details»
Mission, Vision & Core Values of RenovoRx
Oct 19, 2024 [cbm_blg_rlnkng]RenovoRx Mission, Vision & Core Values: RenovoRx is committed to revolutionizing the medical device industry by continuously advancing innovative …See details»
Board of Directors - RenovoRx
Dr. Spiegel brings more than 40 years of biopharmaceutical experience to RenovoRx’s Board. He was involved in more than 30 successful New Drug Application (NDA) approvals by the FDA …See details»
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted ...
1 day ago RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Re...See details»
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ …
Feb 13, 2025 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc.. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology …See details»
Board of Directors :: RenovoRX, Inc. (RNXT)
Dr. Spiegel brings more than 40 years of biopharmaceutical experience to RenovoRx’s Board. He was involved in more than 30 successful New Drug Application (NDA) approvals by the FDA …See details»
RenovoRx Closes $11.1 Million Private Placement, Providing Cash …
Apr 15, 2024 (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local …See details»
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted ...
1 day ago RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing …See details»
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted ...
1 day ago RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to …See details»
RenovoRx Reports Full Year 2021 Financial Results
Los Altos, CA, March 29, 2022 – RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is …See details»